We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
StoneX
SNEX
$8.39B
| $673K | 0.64% |
8,523
-1,898
| -18% | -$142K |
|
52
CytomX Therapeutics
CTMX
$802M
| $662K | 0.63% |
176,407
+146,220
| +484% | +$558K |
|
|
NLOP
53
Net Lease Office Properties
NLOP
$165M
| $654K | 0.63% |
58,791
+34,862
| +146% | +$420K |
|
54
Geron
GERN
$970M
| $633K | 0.61% |
+494,201
| New | +$696K |
|
55
Ooma
OOMA
$642M
| $631K | 0.6% |
32,810
+13,484
| +70% | +$231K |
|
56
Rocky Brands
RCKY
$326M
| $629K | 0.6% |
15,254
+254
| +2% | +$9.93K |
|
57
Janux Therapeutics
JANX
$1.21B
| $620K | 0.59% |
+40,386
| New | +$585K |
|
58
Zoom
ZM
$28.6B
| $615K | 0.59% |
7,125
-14,455
| -67% | -$1.37M |
|
59
Structure Therapeutics
GPCR
$3.38B
| $608K | 0.58% |
11,335
| – | – |
|
60
Avalo Therapeutics
AVTX
$1.02B
| $607K | 0.58% |
+32,827
| New | +$519K |
|
61
Mistras Group
MG
$607M
| $603K | 0.58% |
34,526
| – | – |
|
62
Viemed Healthcare
VMD
$343M
| $603K | 0.58% |
+52,879
| New | +$524K |
|
63
Relmada Therapeutics
RLMD
$466M
| $602K | 0.58% |
86,994
+39,845
| +85% | +$278K |
|
|
CLYM
64
Climb Bio
CLYM
$838M
| $601K | 0.58% |
46,115
-98,425
| -68% | -$1.02M |
|
65
Corbus Pharmaceuticals
CRBP
$222M
| $597K | 0.57% |
63,603
+13,351
| +27% | +$126K |
|
66
Bristol-Myers Squibb
BMY
$139B
| $591K | 0.57% |
+10,263
| New | +$589K |
|
67
Security National Financial
SNFCA
$231M
| $581K | 0.56% |
63,000
| – | – |
|
68
Usana Health Sciences
USNA
$267M
| $557K | 0.53% |
26,068
+8,994
| +53% | +$169K |
|
|
TALK
69
DELISTED
Talkspace
TALK
| $547K | 0.52% |
105,252
-70,299
| -40% | -$365K |
|
70
NVIDIA
NVDA
$5.52T
| $547K | 0.52% |
+2,735
| New | +$562K |
|
71
UroGen Pharma
URGN
$2.19B
| $531K | 0.51% |
+14,440
| New | +$391K |
|
72
AtaiBeckley Inc
ATAI
$2.72B
| $531K | 0.51% |
100,681
-126,989
| -56% | -$535K |
|
73
California Resources
CRC
$4.74B
| $529K | 0.51% |
10,000
-12,500
| -56% | -$770K |
|
74
Cullinan Oncology
CGEM
$1.43B
| $528K | 0.51% |
28,987
+16,383
| +130% | +$243K |
|
75
iBio
IBIO
$83.6M
| $523K | 0.5% |
298,927
+242,609
| +431% | +$434K |
|
Similar funds
IAP
JRSI
SFG
TPW
ACM
TOTUOP
XFP
ICVCFVA
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.